Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse ...

MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha(R) (evolocumab injection) for eligible ...

Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha® (evolocumab injection) for eligible patients following an acute coronary syndrome ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit ...

VESALIUS-CV further extends PCSK9 inhibitor's primary prevention benefits ...

Amgen Inc. (NASDAQ:AMGN) is one of the best pharma stocks to invest in now. Amgen Inc. (NASDAQ:AMGN) announced on March 28 ...

Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.

In this article, we will list the 5 Best Pharma Stocks to Invest In Now. Please visit 7 Best Pharma Stocks to Invest In Now ...

A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Results of lung impedance-guided therapy in HFpEF also anticipated this weekend ...

It’s been a little over two months since President Donald Trump’s direct-to-consumer pharmaceutical site, TrumpRx, launched, ...